ProPhase Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-06-01
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.60, a 90.00% decline year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.00.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $6.00, a 90.01% decline from fiscal 2024.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $60.05, a 594.22% increase from fiscal 2023.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.65, a 12.80% decline from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.92, a 36.08% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $6.00 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | $0.60 10-Q · filed 2025-11-19 | ||||
| 2025-06-30 | $0.60 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $0.60 10-Q · filed 2025-05-20 | ||||
| 2024-12-31 | $60.05 10-K · filed 2026-06-01 | $6.01 10-K · filed 2025-04-01 | |||
| 2024-09-30 | $6.01 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $6.01 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $6.00 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | $8.65 10-K · filed 2025-04-01 | ||||
| 2022-12-31 | $9.92 10-K · filed 2024-03-29 | $10.03 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $9.60 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $6.44 10-Q · filed 2022-08-12 | ||||
| 2021-12-31 | $7.29 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $7.48 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $9.13 10-Q · filed 2021-08-13 | ||||
| 2020-12-31 | $4.58 10-K · filed 2022-03-31 | ||||
| 2019-12-31 | $2.01 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $2.08 10-K · filed 2019-03-26 | ||||
| 2018-06-30 | $2.00 10-Q · filed 2019-08-12 | ||||
| 2017-12-31 | $2.01 10-K · filed 2019-03-26 | ||||
| 2015-12-31 | $1.35 10-K · filed 2016-03-29 | ||||
| 2014-12-31 | $1.39 10-K · filed 2017-02-24 | ||||
| 2013-12-31 | $1.64 10-K · filed 2016-03-29 | ||||
| 2012-12-31 | $1.36 10-K · filed 2015-03-27 | ||||
| 2011-12-31 | $1.10 10-K · filed 2014-03-27 | ||||
| 2010-12-31 | $1.00 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |